Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer

28 Nov 2016

Abstract excerpt

Estrogen receptor α (ERα) is a master driver of a vast majority of breast cancers. Breast cancer cells often develop resistance to endocrine therapy via restoration of the ERα activity through survival pathways. Thus identifying the epigenetic activator of ERα that can be targeted to block ERα gene expression is a critical topic of endocrine therapy. Here, integrative genomic analysis identified MYST3 as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Genomics and Chromatin Dynamics
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27893709
DOI: 10.1038/onc.2016.433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancerPMID 27893709Read ↗

MYSM1 co-activates ERα action via histone and non-histone deubiquitination to confer antiestrogen resistance in breast cancerSemantic proximity Read ↗

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.Semantic proximity Read ↗

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver.Semantic proximity Read ↗

Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.Semantic proximity Read ↗

Amplification of WHSC1L1 regulates expression and estrogen‐independent activation of ERα in SUM‐44 breast cancer cells and is associated with ERα over‐expression in breast cancerSemantic proximity Read ↗

Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancerSemantic proximity Read ↗

TRIM3 Facilitates Estrogen Signaling and Modulates Breast Cancer Cell ProgressionSemantic proximity Read ↗

Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor α.Semantic proximity Read ↗

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancerSemantic proximity Read ↗

Enhancer plasticity in endometrial tumorigenesis demarcates non-coding somatic mutations and 3D-genome alterations boosting the oncogenic driver ESR1Semantic proximity Read ↗

YTHDF3 modulates the progression of breast cancer cells by regulating FGF2 through m6A methylationSemantic proximity Read ↗

MLL3 is a de novo cause of endocrine therapy resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.